Our look is new. Our purpose is the same. Learn more about our brand evolution.
Author: Ashley Ferreira, FSHD Society The REACH Phase 3 clinical trial, conducted by Fulcrum Therapeutics, aimed to evaluate the efficacy of losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD). Despite promising […]
An announcement from Avidity Biosciences to the FSHD community: June 9, 2025 Dear FSHD Community, Today, we are very pleased to share multiple milestones related to the delpacibart braxlosiran (del-brax) […]
Author: Dr. Raymond A. Huml Rare diseases affect millions worldwide, yet treatment options remain scarce. For families like ours who live with Facioscapulohumeral muscular dystrophy (FSHD) – the journey toward […]
Our first-ever FSHD 360 in Ontario, Canada, was a great success, with more than 70 attendees filling the Burnhamthorpe Community Centre in Mississauga on May 3, 2025. We’re delighted to […]
We are busy preparing for World FSHD Day this June 20. World FSHD Day is a global movement to raise awareness of FSHD. From orange slice selfies and proclamations to […]
